Gastrointestinal Neoplasms

The supplied grounding does not support a specific cause or aetiology for gastrointestinal neoplasms overall. It only indicates that genetics, microbiology, and metabolism are studied in relation to these tumors, without defining a single causal pathway.

The grounding supports several biological themes rather than one unified mechanism. Tumor immune response is important, including the prognostic and predictive value of tumor-infiltrating lymphocytes, and the gastrointestinal microbiome is a co-studied mechanism. The literature also reflects pathology-focused staging and characterization of lesions, including the need for accurate histologic assessment in superficial disease.

The supplied grounding does not support general risk factors for gastrointestinal neoplasms overall. It does indicate that immune-related biomarkers such as tumor-infiltrating lymphocytes and prognostic nutritional index have been studied in relation to outcomes, but these are not established risk factors in the provided material.

Management in the supplied grounding includes endoscopic resection approaches for selected superficial gastrointestinal cancers, with endoscopic submucosal dissection used to achieve en bloc resection and accurate pathology staging. For advanced gastrointestinal tract cancers, immune checkpoint inhibitors, particularly anti-PD-1 and anti-PD-L1 therapies, are described as increasingly important, often in combination with chemotherapy in specific settings. The grounding also mentions cell therapy such as claudin18.2-redirected CAR-T therapy in later-line disease.